InvestorNewsBreaks – DarioHealth Corp. (NASDAQ: DRIO) Reports on Clinical Outcomes in Two New Studies at Diabetes Conference

DarioHealth (NASDAQ: DRIO), a leader in the global digital therapeutics (“DTx”) market, reported on the results of two new clinical studies at the 16th International Conference on Advanced Technologies and Treatments for Diabetes (ATTD); the event was held Feb. 22–25, 2023, in Berlin. Specifically, the company reported that one study demonstrated improved clinical outcomes in users diagnosed with Type 2 diabetes; the study also offered analysis to understand the mediating effects of live human coaching and digital interventions across the Dario user journey. The second study exhibited Dario’s ability to reduce hypoglycemic events in older adults who were using a digital chronic condition management solution. The company noted that is committed to evolving its proprietary intelligent digital solutions to support users in developing healthier habits; it also points to the latest research as evidence of how human and digital mechanisms can be optimized in digital health solutions to drive better outcomes and support scaling these solutions in effective and affordable ways. “I am excited to present our latest research on two important areas of interest for our partners and clients,” said Dario vice president of clinical and scientific affairs Yifat Hershcovitz, PhD, in the press release. “Digital health has enormous potential to help people learn to care for their health in sustainable, meaningful ways, and these two new studies offer fresh insights on how we can best achieve those goals.”

To view the full press release, visit https://ibn.fm/DjcvG

About DarioHealth Corp.

DarioHealth Corp. is a leading digital therapeutics (DTx) company revolutionizing how people with chronic conditions manage their health through a user-centric, multichronic condition platform. Dario’s platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain and behavioral health. The company’s user-centric platform offers people continuous and customized care for health, disrupting the traditional episodic approach to healthcare. This approach empowers people to holistically adapt their lifestyles for sustainable behavior change, driving exceptional user satisfaction, retention, and results. Dario provides its highly user rated solutions globally to health plans and other payors, self-insured employers, providers of care and directly to consumers. For more information about the company, please visit www.DarioHealth.com.

NOTE TO INVESTORS: The latest news and updates relating to DRIO are available in the company’s newsroom at http://ibn.fm/DRIO

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@InvestorWire.com

InvestorWire is part of the InvestorBrandNetwork

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.